Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in pediatric moderate-to-severe active Crohn's disease
CTR20244317Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risankizumab in Crohn's disease, sponsored by AbbVie Inc.. Started Apr 2025; status: active.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20244317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244317.